Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03489369 · ClinicalTrials.gov registry record · Phase 1
Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
A Phase 1 study, sponsored by Symphogen A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03489369 is a Phase 1 study that has completed, run by Symphogen A/S. The registered enrollment target is 15 participants.
The verdict
NCT03489369, a Phase 1 study, has completed, sponsored by Symphogen A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is the first study to test Sym022 in humans. The primary purpose of this study is to see if Sym022 is safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available.
Interventions
- DRUG Sym022
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-05-08 |
| Est. Completion | 2020-01-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03489369
The ClinicalTrials.gov registry entry for NCT03489369 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Symphogen A/S, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sym022 is the first listed.
NCT03489369 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03489369 about?
NCT03489369 is a clinical study titled "Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas". This is the first study to test Sym022 in humans. The primary purpose of this study is to see if Sym022 is safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy ...
What is the current status of trial NCT03489369?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2018-05-08. Estimated completion is 2020-01-06.
What interventions are being tested in trial NCT03489369?
The interventions under investigation include: Sym022 (DRUG).
Who is sponsoring clinical trial NCT03489369?
This trial is sponsored by Symphogen A/S, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.